Merck Prostate 365 - Combination therapies for mCRPC (Prostate Cancer)

What is the Purpose of this Study?

We are doing this study to find out if the study drug, pembrolizumab, is a safe and effective treatment for metastatic castrate-resistant prostate cancer when it is given in different combinations with other drugs. Pembrolizumab may work by increasing your immune system's response against a tumor.

What is the Condition Being Studied?

Metastatic Castrate-Resistant Prostate Cancer

Who Can Participate in the Study?

Adults ages 18+ who:

  • Are diagnosed with a type of metastatic castrate-resistant prostate cancer called "neuroendocrine carcinoma"
  • Have previously been treated with a drug called docetaxel

For more information about who can join this study, please contact the study team at

Age Group

What is Involved?

If you choose to join this study, you will:

  • Be assigned to take the study drug, pembrolizumab, in combination with lenvatinib, or MK-7684, or carboplatin + etoposide
  • Have blood draws
  • Give urine samples
  • Have imaging scans (CT and/or MRI)

Pembrolizumab, MK-7684, etoposide, and carboplatin are all drugs taken intravenously (through a needle in a vein in your arm). Lenvatinib is a pill that you take by mouth.

Study Details

Full Title
Phase Ib/II Trial of Pembrolizumab (MK-3475) Combination Therapies in Metastatic Castration-Resistant Prostate Cancer (mCRPC) (KEYNOTE-365)
Principal Investigator
Assistant Professor of Medicine
Protocol Number
IRB: PRO00081276
NCT: NCT02861573
Phase II
Enrollment Status